Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + melphalan
- Development stage
- Unknown
- Lead developer
- Delcath Holdings
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of the antimetabolite fluorouracil and the alkylating agent melphalan. This combination has been studied for treating metastatic or recurrent endometrial carcinoma and other cancers. The combination works through complementary mechanisms of action, with fluorouracil interfering with DNA and RNA synthesis while melphalan cross-links DNA strands to prevent cell division.
- Other names
- 5-FU + melphalanfluorouracil + melphalan
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + melphalan.